Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID’s patent protection now extends to 2030, supporting >10% Y/Y revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback